Literature DB >> 20387011

Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes.

Wahiba Sakly1, Amani Mankaï, Nabil Sakly, Yosra Thabet, Achouak Achour, Leila Ghedira-Besbes, Moncef Jeddi, Ibtissem Ghedira.   

Abstract

Anti-Saccharomyces cerevisiae antibodies (ASCA) have been described in many autoimmune diseases in which there is an increased intestinal permeability. Also in type 1 diabetes (T1D), there is an increased intestinal permeability. Since no data are available about ASCA in T1D, we evaluated, retrospectively, the frequency of ASCA in this disease. ASCA, IgG, and IgA, were determined by ELISA in sera of 224 T1D patients in which coeliac disease has been excluded and 157 healthy control group. The frequency of ASCA (IgG or IgA) was significantly higher in T1D patients than in the control group (24.5% vs. 2.5%, p < 10(-7)). The same observation was found in children and in adult patients when we compare them to healthy children and blood donors group respectively. Compared to children, adult patients with T1D showed significantly higher frequencies of ASCA of any isotype (38% vs. 13.7%, p < 10(-4)), both ASCA IgG and IgA (12% vs. 1.6%, p = 0.002), ASCA IgG (35% vs. 9.8%, p < 10(-5)) and ASCA IgA (15% vs. 5.6%, p = 0.001). The frequency of ASCA was statistically higher in females of all T1D than in males (30.8% vs.17.7%, p = 0.03), in girls than in boys (22% vs.6.2%, p = 0.017), and significantly higher in men than in boys (35.7% vs. 6.2%, p < 10(-4)). The frequency of ASCA IgG was significantly higher than that of ASCA IgA in all T1D patients (21% vs. 9.8%, p < 0.002), in all females (26.5% vs. 10.2%, p < 0.002), in women (37.9% vs. 12%, p < 0.001). The frequency of ASCA was significantly higher in all long-term T1D than in an inaugural T1D (29% vs. 14.5%, p = 0.019). The same observation was found in adults (45.8% vs. 17.8%, p = 0.01). In long-term T1D patients, ASCA were significantly more frequent in adults than children (45.8% vs. 14.5%, p < 10(-4)). The frequency of ASCA IgG was significantly higher in long-term T1D than in an inaugural T1D (25.2% vs. 11.6%, p = 0.03). Patients with T1D had a high frequency of ASCA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20387011     DOI: 10.1007/s12022-010-9118-7

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  39 in total

1.  Endocrine self and gut non-self intersect in the pancreatic lymph nodes.

Authors:  Shannon J Turley; Je-Wook Lee; Nick Dutton-Swain; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-29       Impact factor: 11.205

2.  A unifying hypothesis on the development of type 1 diabetes and celiac disease: gluten consumption may be a shared causative factor.

Authors:  G Frisk; T Hansson; I Dahlbom; T Tuvemo
Journal:  Med Hypotheses       Date:  2008-02-04       Impact factor: 1.538

3.  Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease.

Authors:  A Fasano; T Not; W Wang; S Uzzau; I Berti; A Tommasini; S E Goldblum
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

4.  Anti-Saccharomyces cerevisiae antibodies--a novel serologic marker for Behçet's disease.

Authors:  I Krause; Y Monselise; G Milo; A Weinberger
Journal:  Clin Exp Rheumatol       Date:  2002 Jul-Aug       Impact factor: 4.473

5.  Tissue transglutaminase antibodies in celiac disease, comparison of an enzyme linked immunosorbent assay and a dot blot assay.

Authors:  A Mankaï; W Sakly; H Landolsi; L Gueddah; B Sriha; A Ayadi; M T Sfar; K Skandrani; A Harbi; A S Essoussi; S Korbi; N Fabien; M Jeddi; I Ghedira
Journal:  Pathol Biol (Paris)       Date:  2005-05

6.  Serological responses to microbial antigens in celiac disease patients during a gluten-free diet.

Authors:  Sara Ashorn; Tuuli Välineva; Katri Kaukinen; Merja Ashorn; Jonathan Braun; Hanna Raukola; Immo Rantala; Pekka Collin; Markku Mäki; Tiina Luukkaala; Sari Iltanen
Journal:  J Clin Immunol       Date:  2008-11-06       Impact factor: 8.317

7.  Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment.

Authors:  S Z Aydin; P Atagunduz; M Temel; M Bicakcigil; D Tasan; H Direskeneli
Journal:  Rheumatology (Oxford)       Date:  2007-12-26       Impact factor: 7.580

Review 8.  Autoimmune mechanisms in type 1 diabetes.

Authors:  Mikael Knip; Heli Siljander
Journal:  Autoimmun Rev       Date:  2008-04-30       Impact factor: 9.754

9.  Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele.

Authors:  Mikael Kuitunen; Tero Saukkonen; Jorma Ilonen; Hans K Akerblom; Erkki Savilahti
Journal:  Autoimmunity       Date:  2002-08       Impact factor: 2.815

10.  Screening by anti-endomysium antibodies for celiac disease in Tunisian children with type 1 diabetes mellitus.

Authors:  Amani Mankaï; Hechmi Ben Hamouda; Fethi Amri; Leila Ghedira-Besbes; Abdelaziz Harbi; Mohamed Tahar Sfar; Ahmed Sahloul Essoussi; Moncef Jeddi; Ibtissem Ghedira
Journal:  Gastroenterol Clin Biol       Date:  2007-05
View more
  10 in total

1.  High frequency of antiphospholipid antibodies in primary biliary cirrhosis.

Authors:  Amani Mankaï; Wiem Manoubi; Mariam Ghozzi; Sarra Melayah; Wahiba Sakly; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

Review 2.  Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity.

Authors:  Maurizio Rinaldi; Roberto Perricone; Miri Blank; Carlo Perricone; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

3.  Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis.

Authors:  J Todd Kuenstner; William Chamberlin; Saleh A Naser; Michael T Collins; Coad Thomas Dow; John M Aitken; Stuart Weg; Grzegorz Telega; Kuruvilla John; David Haas; Torsten M Eckstein; Maher Kali; Christine Welch; Thomas Petrie
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  Anti-Saccharomyces cerevisiae antibodies in patients with systemic lupus erythematosus.

Authors:  Amani Mankaï; Wahiba Sakly; Yosra Thabet; Achouak Achour; Wiem Manoubi; Ibtissem Ghedira
Journal:  Rheumatol Int       Date:  2012-04-10       Impact factor: 2.631

5.  Anti Saccharomyces cerevisiae Antibodies in Patients With Anti-β2 Glycoprotein I Antibodies.

Authors:  Amani Mankaï; Skander Layouni; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

6.  Current and future role of biomarkers in Crohn's disease risk assessment and treatment.

Authors:  Cyrus P Tamboli; David B Doman; Amar Patel
Journal:  Clin Exp Gastroenterol       Date:  2011-06-02

Review 7.  Luminex and other multiplex high throughput technologies for the identification of, and host response to, environmental triggers of type 1 diabetes.

Authors:  Sharad Purohit; Ashok Sharma; Jin-Xiong She
Journal:  Biomed Res Int       Date:  2015-03-25       Impact factor: 3.411

Review 8.  Genetics and autoantibodies.

Authors:  Carlo Perricone; Nancy Agmon-Levin; Fulvia Ceccarelli; Guido Valesini; Juan-Manuel Anaya; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2013-07       Impact factor: 4.505

9.  Anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with body fat mass and systemic inflammation, but not with dietary yeast consumption: a cross-sectional study.

Authors:  Anne Stine Kvehaugen; Martin Aasbrenn; Per G Farup
Journal:  BMC Obes       Date:  2017-07-17

10.  Meta-analysis of anti-Saccharomyces cerevisiae antibodies as diagnostic markers of Behçet's disease with gastrointestinal involvement.

Authors:  Linlin Cheng; Liubing Li; Chenxi Liu; Songxin Yan; Yongzhe Li
Journal:  BMJ Open       Date:  2020-10-06       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.